MedDay (France)

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

Ayman Tourbah, Christine Lebrun‐Frénay, Gilles Edan et al. · Multiple Sclerosis Journal · 2016 · 287 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +10

High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference

Marie‐Liesse Piketty, Dominique Prié, Frédéric Sedel et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 2017 · 136 citations

Life Sciences, Biochemistry, Endocrinology +17

MetExplore: collaborative edition and exploration of metabolic networks

Ludovic Cottret, Clément Frainay, Maxime Chazalviel et al. · Nucleic Acids Research · 2018 · 135 citations · Full text

Life Sciences, Biochemistry, Bioinformatics +14

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruce Cree, Gary Cutter, Jerry S. Wolinsky et al. · The Lancet Neurology · 2020 · 104 citations · Full text

Life Sciences, Neurology, Neuroscience +9

Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model

Lodewijk J.A. Toonen, Maurice Overzier, Melvin M. Evers et al. · Molecular Neurodegeneration · 2018 · 77 citations · Full text

Life Sciences, Genetics, Neuroscience +17